Billions of dollars, hundreds of mice and decades of years are sacrificed to research and development for the average pharmaceutical with no guarantee of success. Nothing about that equation makes sense anymore.
And thats why some of the most impressive minds in science are behind Israeli startup Quris,which is rolling out the worlds first clinical-prediction AI (artificial intelligence) platform to evaluate the safety and efficacy of new drugs.
This newly launched, highly scalable automated platform can test thousands of novel drug candidates at once, on hundreds of miniaturized patients-on-a-chip.
Using AI to predict which drug candidates will safely work in humans is expected to improve efficacy and cut drug development costs dramatically.
Israeli Nobel laureate Dr. Aaron Ciechanover and Moderna cofounder Robert S. Langer are actively involved in guiding the science, technology and strategy of Quris, dual-headquartered in Boston and Tel Aviv.
We are at the tipping point of the modernization of drug discovery. I think the Quris platform could be of significant value to pharma companies and the health of society at large, said Langer, one of 12 Institute Professors at MIT.
Saving money and time is the biggest advantage. Eliminating or at least minimizing the use of rodents in drug testing is also important, and not only for animal welfare reasons.
We are not mice, so what works in animal-based trials is not a proper indicator of what will work for people, explained Ciechanover,a physician and research professor at the Technion Israel Institute of Technology in Haifa.
Using a breakthrough way to test drug candidates on miniaturized patients on chips, Quris can demonstrate their safety and efficacy, or lack thereof, through preliminary chip-based clinical trials. This has never been done before, said Ciechanover.
Quris CEO Isaac Bentwich tells ISRAEL21c that AI-driven drug discovery has become the leading frontier for pharma innovation.
However, this wildly expensive technology does not address clinical safety and efficacy. Therefore, most novel drugs still fail clinical trials costing pharma companies more than $30 billion annually.
Quris is the first AI platform to predict which drug candidates will safely work in humans, filling a critical gap in clinical prediction, Bentwich says.
Part of the Quri team in Tel Aviv, with CEO Isaac Bentwich at right. Photo courtesy of Quris
While there are organ-on-chip technologies available to test the effect of drug candidates on, say, the liver, they cannot achieve high throughput.
To generate large amounts of data, you need a platform to perform thousands of experiments, and the current organ-on-a-chip technology does not allow that to happen. Its usually performed one organ at a time, Bentwich explains.
Our chip-on-chip solution does multiple such experiments to train the AI and let the AI define if the drug is safe or not.
Hundreds of genetically diverse patients
Joining together several organs-on-a-chip to build a patient-on-a-chip has proven cumbersome and unscalable, he adds, citing one such device built at Harvard that took up a big box filled with tubes and pipes.
And that was just a single patient-on-a-chip. Our device is two-by-three inches and simulates a hundred patients on a chip by using different architecture and innovations in nanosensing. Its much more scalable and inexpensive, says Bentwich.
Patient-on-a-chip technology will lower the cost and time of drug testing dramatically. Photo courtesy of Quris
Testing to see if a drug is toxic on a single patient-on-a-chip is better than testing it on a mouse. But its not perfect because different people react differently to the same drug, he adds.
Heres where Quris exclusive partnership with the New York Stem Cell Foundation (NYSCF) Research Institutecomes in.
We generate stem cells, and from them different organs, so you have an entire clinical trial on a chip before testing on humans, Bentwich explains.
By testing thousands of drugs known to be safe or unsafe on male and female patients-on-a-chip from different genomic makeups, we are able to train the AI to create representative samples of populations based on many properties.
First clinical trial for Fragile-X drug
Pharma companies can use Quris platform to develop safer drugs faster. At the same time, Quris is using its platform to develop its own pharmaceuticals.
And it made sense to focus on rare genetic diseases that cannot be modeled in mice and arent common enough to attract development dollars.
The first Quris drug addresses Fragile X Syndrome, the most common inherited cause of autism and intellectual disabilities worldwide. This drug candidate was developed initially at the Hebrew University of Jerusalem.
Our Fragile X Syndrome drug is moving into clinical testing in the first half of 2022, says Bentwich, noting that most AI pharma companies do not have drugs at the human clinical testing phase.
Five years to market
This will be a test case to demonstrate how our system can bring a drug to market in five years with millions of dollars, not 20 years with billions, says Bentwich.
We are focusing generally on central nervous system disorders. Brain and liver diseases and cancer are the three areas where safety and efficacy failures of drugs are especially high, he says.
In addition to 18 granted and pending patents, Quris has partnerships with the Technion for various aspects of development, with Tel Aviv University in nanotechnology, and with Hebrew Universitys NewStem drug-discovery spinoff.
The company is doing all this with a lean team of about 20.
Some of the Quris team in Tel Aviv. Photo courtesy of Quris
Its very moving to see extremely talented young guys fresh out of army, not very experienced, working alongside experienced biologists, chemists, nano scientists, micromechanics and robotics experts, using bioconvergenceto solve big problems, says Bentwich.
Dr. Kobi Richter, founder and chief technology officer of Medinol, explained why he participated in Quris recent $9 million seed round.
Our drug discovery process is broken, and technology darlings across biotech, artificial intelligence, machine learning and big data have not been able to overcome the colossal clinical trial failure rate, said.
With a remarkable team of scientific pioneers at the helm and its extraordinary clinical prediction platform, Quris will be a gamechanger for the industry and lead the next era of drug discovery, Richter said.
For more information, click here
See the rest here:
No animals harmed in new chip drug tests that are faster and cheaper - ISRAEL21c
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world's largest cultivated meat... - October 13th, 2022
- The New York Stem Cell Foundation Mourns the Loss of CEO Susan L. Solomon - October 4th, 2022
- In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy? - Targeted Oncology - October 4th, 2022
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Benzinga - October 4th, 2022
- Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference - Sernova (OTC:SEOVF) - Benzinga - October 4th, 2022
- New Study Finds Mouse Embryonic Stem Cells Have No Special - September 25th, 2022
- GMAs Robin Roberts replaced by Cecilia Vega as host is still absent from morning show following emotional... - The US Sun - September 25th, 2022
- Severe COVID-19 caused by senile interferon response in older patients, researchers suggest - EurekAlert - September 25th, 2022
- Money on the Move: Arsenal, ILiAD and a Hefty Gift to UCSD - BioSpace - September 8th, 2022
- How surviving cancer changed this 34-year-olds attitude toward work: The concept of checking email was laughable - CNBC - September 8th, 2022
- Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer - Benzinga - September 8th, 2022
- 6 Ingredients to Avoid Putting on Your Skin - Healthline - September 8th, 2022
- Scientists create 'synthetic' embryo with brain, beating heart in 'world first' - New York Post - August 30th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 30th, 2022
- Pelvic Reconstruction Market is projected to reach a valuation of US$ 366.9 million by 2032, at a CAGR of 2.8% during 2022-2032 Future Market... - August 30th, 2022
- Global Mesenchymal Stem Cell (MSC) Market to Grow at a CAGR of ~14% during 2022-2031; Market to Grow on the Back of Increasing Prevalence of Chronic... - August 5th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 5th, 2022
- Global Hematopoietic Stem Cell Transplant (HSCT) Market to be Driven by Increasing Prevalence of Blood Ca - Benzinga - August 5th, 2022
- Why Are There so Many Books and Shows About Cannibalism? - The New York Times - July 27th, 2022
- Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal - July 27th, 2022
- Herminia Pasantes revealed one of taurines big roles in the brain - Science News Magazine - July 27th, 2022
- Shai Efrati, MD, the World's Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit - PR Web - July 27th, 2022
- Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom... - The US Sun - July 27th, 2022
- Melanoma Kills Nearly Twice The Number Of Men Than Women: Study - Kaiser Health News - July 19th, 2022
- Patients have turned to pricey 'blood washing' to treat long COVID - New York Post - July 19th, 2022
- Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) -... - July 11th, 2022
- Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 - Digital Journal - July 11th, 2022
- 'World's Greatest Tuba-Playing Car Salesman' Bounces Back after Leukemia, Thanks to Wilmot Team - URMC - July 3rd, 2022
- Hadjiargyrou Is New York Tech's First Distinguished Professor | Box | New York Tech - New York Institute of Technology - July 3rd, 2022
- The global tissue engineering market is anticipated to reach US$ 13,236.87 million in 2022 and is project - Benzinga - July 3rd, 2022
- He Helped Cure the London Patient of H.I.V. Then He Turned to Covid. - The New York Times - June 13th, 2022
- Biden to Pause New Solar Tariffs as White House Aims to Boost Adoption - The New York Times - June 13th, 2022
- Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference - Business Wire - June 4th, 2022
- ReCode Therapeutics to Present at Jefferies Healthcare Conference - Benzinga - Benzinga - June 4th, 2022
- A Medical History of Transplant Surgery Thats Not for the Squeamish - The New York Times - May 15th, 2022
- Mesenchymal Stem Cells Market to Witness Growth Acceleration | Celprogen Inc., Thermo Fisher Scientific, Inc. Queen Anne and Mangolia News - Queen... - May 15th, 2022
- CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors - Business Wire - May 15th, 2022
- William Blair Begins Coverage on Century Therapeutics (NASDAQ:IPSC) - Defense World - May 15th, 2022
- Aging Brain Initiative awards fund five new ideas to study, fight neurodegeneration - MIT News - May 2nd, 2022
- Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia - PR Newswire - May 2nd, 2022
- What's Trending in the World of Hair Treatments - NewBeauty Magazine - May 2nd, 2022
- Demand in the US Animal Model Market is set to Increase at a 4.1% CAGR from 2022 to 2032 - Future Market Insights - PR Newswire - May 2nd, 2022
- Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North... - April 19th, 2022
- BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure - GlobeNewswire - March 25th, 2022
- Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance - Yahoo Finance - March 25th, 2022
- Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 24th, 2021
- 2021: The year in review | YaleNews - Yale News - December 24th, 2021
- 15 Truly Unbelievable Ways Science Changed the World in 2021 - Fatherly - December 24th, 2021
- Cargo Dragon Docks to Station with Brand New Science - NASA - December 24th, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 24th, 2021
- Cytovia Therapeutics' Scientific Leadership to Present at Upcoming Conferences - Business Wire - December 10th, 2021
- A New Stem-Cell Treatment Looks to Have Cured a Man of Type 1 Diabetes - Good News Network - December 10th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - PRNewswire - December 10th, 2021
- Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma ... - The Bakersfield Californian - December 10th, 2021
- Stem Cell Therapy for Heart Failure Reduced Major Cardiac Events and Death - Diagnostic and Interventional Cardiology - November 22nd, 2021
- Global Cord Blood Stem Cells Market With An Annual Growth Rate, The Impact Of Covid-19: FAQ The UK Directory - The UK Directory - November 22nd, 2021
- The Beauty Products Violet Greys Cassandra Grey Uses to the Last Drop - The Cut - November 22nd, 2021
- Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual... - October 16th, 2021
- Holy wars against vaccines and science People's World - People's World - October 16th, 2021
- Judge Rules to Uphold Religious Exemption to NY Vax Mandate - wnbf.com - October 16th, 2021
- Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial - OncLive - October 16th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - KKTV 11 News - October 5th, 2021
- Coronavirus: What's happening in Canada and around the world on Tuesday - CBC.ca - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Court hears dispute over N.Y. healthcare workers seeking COVID vaccine religious exemption - Washington Times - October 5th, 2021
- Glioma subtype may hold the secret to the success of immunotherapies - Michigan Medicine - October 5th, 2021
- Vera Nall: Misinformation will kill us in Southwest Missouri - Joplin Globe - October 5th, 2021
- Meet the Newest Group of Tenured, Tenure-Track Faculty at UT Dallas - University of Texas at Dallas - October 5th, 2021
- Global Stem Cell Banking Market to Reach US$11.3 Billion by the Year 2027 - Yahoo Finance - August 5th, 2021
- COVID-19 Antibody Therapy Now Available For Treatment and Post-Exposure Prophylaxis - PrecisionVaccinations - August 5th, 2021
- Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo... - August 5th, 2021
- BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment... - August 5th, 2021
- 5 days, 11 life science IPOs & more than $1.3B in new capital - MedCity News - August 5th, 2021
- What Its Like To Have Severe Iron Deficiency Anemia - Scary Mommy - August 5th, 2021
- 'Black fungus' infections on the rise in India: report - New York Post - June 23rd, 2021
- Global Cord Stem Cell Banking Market Status, Business Trends, Competitive Analysis, Growth Factors and Forecasts To 2028||Cryo-Cell International,... - June 23rd, 2021
- Turning to Books to Grasp the Most Ungraspable Disease - The New York Times - June 23rd, 2021